Automated Recording
System Announcement
Replay available
Perimeter Medical Imaging AI, Inc. (PINK) Q4 2025 Earnings Call
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) Q4 2025 earnings conference call, held 2026-03-31. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Stephen Kilmer
Investor Relations
Sarah Bryan
Chief Financial Officer
Adrian Mendez
Chief Executive Officer
Michael Freeman
Analyst, Raymond James
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Perimeter Medical Imaging Ai Inc.
Replay transcript excerpt
WEBVTT 00:00:22.087 -- 00:00:24.087 Thank 00:00:27.815 -- 00:00:29.815 you. 00:01:59.303 -- 00:02:01.303 Thank 00:02:28.707 -- 00:02:30.707 you. 00:02:40.023 -- 00:02:42.023 We'll 00:02:46.652 -- 00:02:48.652 be 00:02:49.376 -- 00:02:51.376 right 00:02:55.825 -- 00:02:57.825 back. 00:04:21.087 -- 00:04:23.087 Thank 00:04:23.999 -- 00:04:25.999 you. 00:04:59.950 -- 00:05:05.215 Good afternoon, ladies and gentlemen. Welcome to the Perimeter Medical fourth quarter 00:05:05.215 -- 00:05:10.660 2025 conference call. At this time, all lines are in listen-only 00:05:10.660 -- 00:05:12.101 mode. 00:05:12.101 -- 00:05:16.985 Following the presentation, we will conduct a question and answer session. 00:05:16.985 -- 00:05:21.889 If at any time during this call you require immediate assistance, please press star zero 00:05:21.889 -- 00:05:23.791 for the operator. 00:05:23.791 -- 00:05:28.934 This call is being recorded on Tuesday, March 31st of 2026. 00:05:29.178 -- 00:05:33.663 I would now like to turn the conference over to Stephen Kilmer, Investor Relations. 00:05:33.663 -- 00:05:36.024 Please go ahead. 00:05:36.687 -- 00:05:39.130 Thank you. Good afternoon, everyone. 00:05:39.130 -- 00:05:43.595 Let me start by pointing out that this conference call will include forward-looking statements 00:05:43.595 -- 00:05:46.618 within the meaning of applicable securities laws. 00:05:46.618 -- 00:05:50.923 These may include statements regarding the future financial position, business strategy 00:05:50.923 -- 00:05:55.949 and strategic goals, commercial activities and timing, competitive conditions, 00:05:55.949 -- 00:06:01.338 research and development activities, projected costs and capital expenditures, research 00:06:01.338 -- 00:06:06.262 and clinical testing outcomes, the potential ...